Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MLYS vs TLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–1 Matrix Metrics)

TLX Overall Winner 6-Pillar Tally: MLYS 1 – 5 TLX Matrix Metrics: MLYS 1 – 8 TLX

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over Mineralys Therapeutics, Inc. (MLYS) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLYS carries a Unified Composite Score of 58.9/100 (HOLD) at $14.74 (N/M Forward P/E, 0.0% operating margin), whereas TLX carries 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin).

  • Composite vs. Pillar Nuance: While MLYS currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. TLX 46.4/100 HOLD), TLX captures the overall institutional head-to-head verdict (8–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (6.2% vs. 0.0% operating margin) and revenue trajectory (+22.3% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: MLYS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3); meanwhile TLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLYS vs TLX
MLYS NASDAQ
Mineralys Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$14.74
-3.85% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.70β · 89% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 68.0 Fund 68.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.2%), weak momentum, RSI 30
RSI-14: 30.3 · SMA20: $17.97 · SMA50: $22.39
TLX NASDAQ Head-to-Head Winner
Telix Pharmaceuticals Limited American Depositary Shares
Pharmaceutical Preparations
$8.96
-2.98% 1D
Market Cap $3.2B
TTM Revenue $891M
Forward P/E N/M
Beta / 30D Vol 0.84β · 62% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 64.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.7%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $9.46 · SMA50: $10.61

6-Pillar Scorecard Institutional Category Breakdown (MLYS 1 – 5 TLX)

Columns: Metric · MLYS · TLX
1. Valuation Multiples TLX
Forward P/E N/M N/M
Trailing P/E N/M 93.6x
PEG Ratio N/M N/M
EV / Revenue N/M 3.6x
2. Growth & Scale TLX
Revenue Growth (YoY) +0.0% +22.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $891M
Market Cap $1.4B $3.2B
3. Profitability & Quality TLX
Gross Margin N/A 47.6%
Operating Margin 0.0% 6.2%
Net Profit Margin 0.0% 3.8%
Return on Equity (ROE) -68.5% 7.4%
4. Balance Sheet & Cash Flow TLX
Cash Generation (TTM) -$153M $70M EBITDA
Cash Flow Margin N/A 7.8% EBITDA Mgn
Net Cash / Leverage $3.0M Net Cash $1.44 Book/Sh · 7.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MLYS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 89.9% (39th %ile) N/A (N/A)
Put/Call OI Skew 0.21x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat TLX
OpEx & R&D Intensity N/A 41.4% of Rev ($369M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLYS (1) vs TLX (8)
Institutional Metric MLYS TLX Criterion Row Edge
Market Capitalization
Scale
$1.4B $3.2B Larger Scale TLX
Trailing P/E Ratio
Valuation
N/M 93.6x Lower Multiple TLX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +22.3% Higher Growth TLX
Operating Margin (TTM)
Profitability
0.0% 6.2% Higher Margin TLX
Net Profit Margin
Profitability
0.0% 3.8% Higher Margin TLX
Return on Equity (ROE)
Capital Efficiency
-68.5% 7.4% Higher ROE TLX
52-Week Range Position
Momentum
0% ($15–$47) 39% ($6–$13) Stronger Trend TLX
Beta / 30D Volatility
Risk Regime
1.70β · 89% Vol 0.84β · 62% Vol Lower Realized Risk TLX
Unified Institutional Score
Composite Signal
58.9 / 100 (HOLD) 46.4 / 100 (HOLD) Higher Composite MLYS
Trailing 12M Revenue (USD)
Operating Scale
N/A $891M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 47.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$153M ($3.0M Net Cash) $70M EBITDA ($1.44 Book/Sh · 7.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLX +11.16 pp
MLYS: -27.39% · TLX: -16.23%
3M Horizon TLX +19.99 pp
MLYS: -44.61% · TLX: -24.62%
6M Horizon TLX +31.26 pp
MLYS: -44.15% · TLX: -12.89%
1Y Horizon TLX +60.88 pp
MLYS: -66.72% · TLX: -5.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLYS vs TLX. Trailing 12-month operating profitability (MLYS 0.0% vs TLX 6.2%) and valuation multiples (MLYS N/M vs TLX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MLYS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-68.5% · N/M
TLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$891M
Gross Margin47.6%
Op. Margin6.2%
ROE / Fwd P/E7.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLYS BREAKDOWN
119d in phase · OBV NEUTRAL
Current IV 89.9%
IV Percentile 39th %ile
Put/Call OI Skew 0.21x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MLYS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLYS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TLX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment 41.4% of Rev ($369M)
90D Engineering Disclosures 0 Published

Investor FAQ MLYS vs TLX Key Questions & Quantitative Answers

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over Mineralys Therapeutics, Inc. (MLYS) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLYS carries a Unified Composite Score of 58.9/100 (HOLD) at $14.74 (N/M Forward P/E, 0.0% operating margin), whereas TLX carries 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin). Composite vs. Pillar Nuance: While MLYS currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. TLX 46.4/100 HOLD), TLX captures the overall institutional head-to-head verdict (8–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (6.2% vs. 0.0% operating margin) and revenue trajectory (+22.3% vs. +0.0% YoY). Technical & Structure Timing Caution: MLYS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3); meanwhile TLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLX leads the Growth & Scale pillar: MLYS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TLX at +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin). On trailing 12-month operating scale, MLYS generates N/A in USD-normalized revenue versus $891M for TLX. In operating R&D and SG&A reinvestment, MLYS deploys N/A (0 90-day corporate R&D disclosures) versus 41.4% of Rev ($369M) (0 disclosures) for TLX.

TLX screens cheaper on headline valuation multiples. MLYS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLYS (-68.5% ROE) versus TLX (7.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MLYS carries 89.9% implied volatility (39th %ile, Balanced (25th–60th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 89% Vol realized risk). By comparison, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Telix Pharmaceuticals Limited American Depositary Shares (TLX) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.